Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by stockman75on Aug 12, 2021 7:51am
95 Views
Post# 33690472

RE:RE:RE:RE:Funny, Guess they allow dogs in the office?

RE:RE:RE:RE:Funny, Guess they allow dogs in the office?For me the most concerning aspect of the story is lack of insider ownership. Maybe easier to smile when you have little skin in the game? 

Some of the insiders surely would be getting a little greedy if the results are that fantastic so far in oncology and if their confidence is so high. For me it is the biggest part of the story that is missing.  I share some of the cynicism but since next to nothing is priced in for oncology or NASH there is still plenty of upside if either one turns out as even a partial win. 

canadapiet wrote: OMG!!!
Amazing! 
"Ridculously low shareprice" .............., i'm sure he ment to say: "ridiculously low insider ownership"!!!!! 

They give no sign or whatsoever that shareprice is ridiculously low, on the contrary!! 
First that horrible offer, then "NASH" on hold (searching for a partner after years of waiting for the P3 is putting them in a weak position, certainly after telling that it would be a pitty to "partner" if you are so close with a "mechanism" in such a lucrative market......., their own words!!!!!!), and for now nothing new on the "oncology" front......

But hey, there is still "HOPE" (again, over and over and over again....)


Becoming a sad story 


SPCEO1:

Paul gets the biggest applause from me for his comment about the stock price being "ridiculously low" given what TH has going on in cancer. Just for saying that he took the grade on the Weekly Report Card up at least one level! If he does not believe that to be the case, it will be harder for others to believe it.


<< Previous
Bullboard Posts
Next >>